Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website
07 March 2013
(165.07 Kb 48 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013